Web Exclusives

Web Exclusives — May 14, 2024
Despite ranking among the top 6 wealthiest economies in the world per capita, the United States still has sizable health disparities among its citizens, which are rooted in social, economic, and environmental factors. Place of birth is more strongly associated with life expectancy than race or genetics.
Read Article

Web Exclusives — April 15, 2024
Recognizing the complexities of treatment with oral medications is an important step toward successful outcomes.
Read Article

Web Exclusives — August 7, 2023
On July 19, 2023, an EF3 tornado touched down in Rocky Mount, NC, badly damaging a Pfizer drug manufacturing facility that is responsible for producing nearly 25% of Pfizer’s sterile injectable medicines used in US hospitals.
Read Article

Web Exclusives — January 31, 2023
One-year follow-up data from a phase 3 study found similar duration of response, time to progression (TTP), and survival rates with the biosimilar candidate CT-P16 compared with its reference drug, bevacizumab (Avastin), in the first-line treatment of patients with metastatic or recurrent nonsquamous non–small-cell lung cancer (NSCLC).
Read Article

Web Exclusives — December 5, 2022
In an interview, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Read Article

Web Exclusives — October 19, 2021
Recently released study results indicate whole-body MRI is superior to bone scan for prognosis in patients with metastatic hormone-naïve prostate cancer.
Read Article

Web Exclusives — October 19, 2021
Recently released analysis of 18F-DCFPyL PET/CT accuracy demonstrated improved diagnostic capability in men with biochemical recurrence of prostate cancer.
Read Article

Web Exclusives — October 19, 2021
NaF PET imaging study demonstrates an increased sensitivity over Tc99m-MDP bone scans for new lesion detection in patients with stable metastatic prostate cancer.
Read Article

Web Exclusives — October 19, 2021
Gallium-68 PSMA PET/CT imaging in patients with early relapsed prostate cancer confirms the reliability of this imaging modality in local and metastatic lesion detection.
Read Article

Web Exclusives — October 19, 2021
Salvage radiotherapy decisions for patients with recurrent prostate cancer after prostatectomy change after 18F-fluciclovine PET/CT reveals higher positive findings than conventional imaging.
Read Article

Page 1 of 11